Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BEBT-908 in Relapsed or Refractory Diffuse Large B-Cell Lymphoma
CTR20200035Phase 2Completed
- Sponsor
- Bibet Pharmaceutical
- Start
- Feb 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ifupinostat in diffuse large B-cell lymphoma (DLBCL), sponsored by Bibet Pharmaceutical. Started Feb 2020; status: completed.
02
Drugs
ifupinostat
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on CTR20200035.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20200035.